Alaunos Reports New Preclinical Data Supporting ALN1003's Liver Benefits
TCRT sits 41% above its 52-week low of $1.67.
Summary
Alaunos Therapeutics released new preclinical data for its obesity drug candidate, ALN1003, showing additional evidence of liver benefits in mouse studies, which could aid in its ongoing search for financing.
Key Events · Product Development and Regulatory · TCRT
-
New Preclinical Data
New statistical analysis from a 48-day diet-induced obesity mouse study of ALN1003 showed lower liver weight in treated animals after adjusting for body fat percentage.
-
Consistency with Prior Findings
This new finding is directionally consistent with previously reported data on lower liver injury enzymes, selected histology, HOMA-IR, and favorable adipose endocrine biomarkers.
-
Early Stage & Limitations Noted
The company emphasized that these are non-GLP preclinical studies, and findings from mouse models may not translate to human efficacy or safety.
-
Critical Financial Context
The company reiterated its critical cash position of $0.35 million as of March 31, 2026, and its ongoing need to pursue additional financing.
Analysis · TCRT · Life Sciences
Alaunos Therapeutics announced new statistical analysis from a preclinical mouse study of its obesity drug candidate, ALN1003. The analysis shows lower liver weight after adjusting for body fat, which is consistent with prior positive findings. This update provides further scientific support for ALN1003's potential, which is crucial for the company as it faces significant financial challenges and seeks additional funding.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRT was trading at $2.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $1.67 to $6.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.